Mitochondrial dysfunction plays a key role in the abrogation of cardioprotection by sodium hydrosulfide post-conditioning in diabetic cardiomyopathy rat heart

  • Mahalakshmi A
  • Gino A. KurianEmail author
Original Article


Our previous study demonstrated that hydrogen sulfide post-conditioning (HPOC) renders cardioprotection against ischemia-reperfusion (I/R) injury in normal rat by preserving mitochondria. But its efficacy in ameliorating I/R in the diabetic heart with (DCM) or without cardiomyopathy (DM) is unclear and is the focus of the present study. Normal (N), diabetes mellitus (streptozotocin, 35 mg/kg; normal diet), and DCM (streptozotocin, 35 mg/kg; high-fat diet) rats were subjected to I/R (30 min global ischemia followed by 60 min reperfusion) in presence and absence of HPOC using ex vivo Langendorff perfusion system. At the end of heart perfusion, subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM) fractions from the tissue were isolated and measured for the ATP production, electron transport chain (ETC) enzyme activity, and membrane potential. The prominent I/R-associated injury in DCM rat was not subsequently attenuated by HPOC protocol unlike in the normal or diabetic rat heart (latter rat heart showed moderate protection) (HPOC recovery on infarct size: N 75% vs. DM 63% vs. DCM 48%). The baseline ATP content and subsequent ATP-producing capacity in DCM rat heart were low as compared with those in normal or DM rat heart, especially in SSM. HPOC protocol reversed the I/R-induced low mitochondrial ATP content and low ATP-producing capacity (both in non-energized and energized with glutamate/malate) significantly in normal and DM hearts, but not in DCM heart. Moreover in DCM, decreased activity of mitochondrial electron chain enzymes (complexes I, II, III, and IV) in SSM (26%, 88%, 57%, and 17%) and IFM (76%, 89%, 60%, and 13%) from sham control was maintained even after the conditioning of heart with hydrogen sulfide donor. Results altogether suggest that significantly higher levels of perturbing mitochondria in DCM rat heart underline the deteriorated cardiac recovery by HPOC.


Diabetes mellitus Diabetic cardiomyopathy Ischemia-reperfusion injury Subsarcolemmal mitochondria Interfibrillar mitochondria 



The authors sincerely thank the Department of Science and Technology for providing INSPIRE fellowship (DST/INSPIRE Fellowship/2013/326).

Authors’ contributions

Dr. Gino A Kurian has designed the work and helped in data interpretation and writing the manuscript. Ms. Mahalakshmi A has executed the experiments, analyzed the data, interpreted the results, wrote the manuscript, and compiled the literature sources.

Compliance with ethical standards

All procedures for the handling of the animals during the investigations were reviewed and approved by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA Approval No. 300/SASTRA/IAEC/RPP), India.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

210_2019_1733_MOESM1_ESM.docx (1.4 mb)
ESM 1 (DOCX 1462 kb)


  1. Algeria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S (2007) Collaborative Organization of RheothRx Evaluation (CORE) Trial Investigators infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J 154:743–750CrossRefGoogle Scholar
  2. Ansari SB, Kurian GA (2016) Hydrogen sulfide modulates sub-cellular susceptibility to oxidative stress induced by myocardial ischemic reperfusion injury. Chem Biol Interact 252:28–35CrossRefGoogle Scholar
  3. Banu SA, Ravindran S, Kurian GA (2016) Hydrogen sulfide post-conditioning preserves interfibrillar mitochondria of rat heart during ischemia reperfusion injury. Cell Stress Chaperones 21(4):571–582CrossRefGoogle Scholar
  4. Baracca A, Sgarbi G, Solaini G, Lenaz G (2003) Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F0 during ATP synthesis. Biochim Biophys Acta Bioenerg 1606(1–3):137–146CrossRefGoogle Scholar
  5. Bibli SI, Andreadou I, Chatzianastasiou A, Tzimas C, Sanoudou D, Kranias E, Brouckaert P, Coletta C, Szabo C, Kremastinos DT, Iliodromitis EK (2015) Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc Res 106:432–442CrossRefGoogle Scholar
  6. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ (2009) Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 105:365–374CrossRefGoogle Scholar
  7. Chatzianastasiou A, Bibli SI, Andreadou I, Efentakis P, Kaludercic N, Wood ME, Whiteman M, Di Lisa F, Daiber A, Manolopoulos VG, Szabó C (2016) Cardioprotection by H2S donors: nitric oxide-dependent and -independent mechanisms. J Pharmacol Exp Ther 106:432–442Google Scholar
  8. Chinopoulos C, Starkov AA, Fiskum G (2003) Cyclosporin A-insensitive permeability transition in brain mitochondria: inhibition by 2-aminoethoxydiphenyl borate. J Biol Chem 278:27382–27389CrossRefGoogle Scholar
  9. Croston TL, Thapa D, Holden AA, Tveter KJ, Lewis SE, Shepherd DL, Nichols CE, Long DM, Olfert IM, Jagannathan R, Hollander JM (2014) Functional deficiencies of subsarcolemmal mitochondria in the type 2 diabetic human heart. Am J Physiol Heart Circ Physiol 307(1):H54–H65CrossRefGoogle Scholar
  10. Dabkowski ER, Baseler WA, Williamson CL, Powell M, Ra-zunguzwa TT, Frisbee JC, Hollander JM (2010) Mito-chondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol Heart Circ Physiol 299:H529–H540CrossRefGoogle Scholar
  11. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97:12222–12226CrossRefGoogle Scholar
  12. Duncan JG (2011) Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta Mol Cell Res 1813(7):1351–1359CrossRefGoogle Scholar
  13. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H (2007) Hydrogen sulfide attenuates myocardial ischemia–reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 104:15560–15565CrossRefGoogle Scholar
  14. Frazier AE, Thorburn DR (2012) Biochemical analyses of the electron transport chain complexes by spectrophotometry. Methods Mol Biol 837:49–62CrossRefGoogle Scholar
  15. Galderisi M, Anderson KM, Wilson PW, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68:85–89CrossRefGoogle Scholar
  16. Hine C, Kim HJ, Zhu Y, Harputlugil E, Longchamp A, Matos MS, Ramadoss P, Bauerle K, Brace L, Asara JM, Ozaki CK (2017) Hypothalamic-pituitary axis regulates hydrogen sulfide production. Cell Metabol 25(6):1320–1333CrossRefGoogle Scholar
  17. Kurian GA, Berenshtein E, Kakhlon O, Chevion M (2012) Energy status determines the distinct biochemical and physiological behavior of interfibrillar and sub-sarcolemmal mitochondria. Biochem Biophys Res Commun 428(3):376–382CrossRefGoogle Scholar
  18. Lambert JP, Nicholson CK, Amin H, Amin S, Calvert JW (2014) Hydrogen sulfide provides cardioprotection against myocardial/ischemia reperfusion injury in the diabetic state through the activation of the RISK pathway. Med Gas Res 4:20–31CrossRefGoogle Scholar
  19. Mahalakshmi A, Kurian GA (2018) Evaluating the impact of diabetes and diabetic cardiomyopathy rat heart on the outcome of ischemia-reperfusion associated oxidative stress. Free Radic Biol Med 118:35–43CrossRefGoogle Scholar
  20. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ (2007) Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD trial). Am J Cardiol 100:206–210CrossRefGoogle Scholar
  21. Miki T, Yuda S, Kouzu H, Miura T (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18(2):149–166CrossRefGoogle Scholar
  22. Murphy E (2004) Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94(1):7–16CrossRefGoogle Scholar
  23. Palmer JW, Tandler B, Hoppel CL (1977) Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 252(23):8731–8739PubMedGoogle Scholar
  24. Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, Calvert JW (2013) Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol 304(9):H1215–H1224CrossRefGoogle Scholar
  25. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602CrossRefGoogle Scholar
  26. Si YF, Wang J, Guan J, Zhou L, Sheng Y, Zhao J (2013) Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. Br J Pharmacol 169(3):619–631CrossRefGoogle Scholar
  27. Skulachev VP (2001) Mitochondrial filaments and clusters as intracellular power-transmitting cables. Trends Biochem Sci 26:23–29CrossRefGoogle Scholar
  28. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P (2011) Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 92(1):10–18CrossRefGoogle Scholar
  29. Voulgari C, Papadogiannis D, Tentolouris N (2010) Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 6:883CrossRefGoogle Scholar
  30. Ye P, Gu Y, Zhu YR, Chao YL, Kong XQ, Luo J, Ren XM, Zuo GF, Zhang DM, Chen SL (2018) Exogenous hydrogen sulfide attenuates the development of diabetic cardiomyopathy via the FoxO1 pathway. J Cell Physiol 233(12):9786–9798CrossRefGoogle Scholar
  31. Zhou X, Feng Y, Zhan Z, Chen J (2014) Hydrogen sulfide alleviates diabetic nephropathy in a streptozotocin-induced diabetic rat model. J Biol Chem 289(42):28827–28834CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Vascular Biology Laboratory, School of Chemical and BiotechnologySASTRA UniversityThanjavurIndia

Personalised recommendations